Plasma beta-endorphin concentration in infants with apneic spells

Area of Science:

• Neonatology
• Neuroendocrinology
• Pediatric Research

Background:

• Apnea of prematurity is a common respiratory challenge in newborns.
• The role of endogenous opioids in neonatal cardiorespiratory control is not fully understood.
• Beta-endorphin (beta-ED) is a key endogenous opioid peptide with potential physiological effects.

Purpose of the Study:

• To investigate the correlation between plasma beta-endorphin concentrations and the occurrence of apnea in preterm infants.
• To compare beta-ED levels in preterm infants with different apnea severities.

Main Methods:

• Plasma beta-endorphin concentrations were measured in three groups of preterm infants: controls, those with apnea and bradycardia, and those with apnea alone.
• Infant groups were characterized by gestational age, birthweight, and postnatal age.

Main Results:

• Plasma beta-endorphin concentrations were significantly elevated in infants with severe apnea and bradycardia (68.0 +/- 9.0 pg/ml) compared to controls (26.9 +/- 2 pg/ml) and infants with apnea alone (39.6 +/- 2.0 pg/ml).
• The severity of apnea, particularly when accompanied by bradycardia, was associated with increased beta-ED levels.

Conclusions:

• Elevated plasma beta-endorphin concentrations are associated with severe apneic spells in preterm infants.
• These findings suggest that endogenous opiates, such as beta-ED, may play a role in the pathophysiology of apnea of prematurity.